Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
KWS SAAT SE & Co. KGaA
KWS breeds and sells seeds — mostly corn, sugarbeet, and cereals — to farmers around the world.
KWS is a plant breeding company. It doesn't just multiply seeds and sell them; it runs the long, patient work of genetics — crossing plants, testing them in fields, and selecting the ones that yield more, resist disease, or survive drought — and then sells that improved seed to farmers. When a farmer buys KWS sugarbeet or corn seed, they're paying for years of breeding that they hope will show up as a better harvest.
The business is mostly built on three crops: corn (chiefly in the Americas), sugarbeet (where KWS is the global leader by a wide margin), and cereals like wheat, barley, and rye. Sugarbeet is a small-acreage, high-value crop — a farmer planting it cares a lot about getting the best seed — while corn is a huge market with fierce competition from much bigger players like Bayer and Corteva. KWS also has a vegetables seed business and a growing unit using gene-editing tools such as CRISPR to speed up breeding, a technology that regulators in Europe have been slowly warming to. Headquartered in Einbeck, in Lower Saxony, Germany, KWS is a family-controlled company — the families still hold a big chunk of the shares — and it's been in the seed business since the 1850s, originally as a sugarbeet breeder. That heritage matters: sugarbeet is where it has its deepest moat, because breeding know-how compounds over decades and farmers stick with seed varieties they trust.
The economics of seed breeding are attractive but slow. Once a new variety is developed, selling more of it costs relatively little, so profits can scale nicely. But breeding takes years, and the company spends heavily on research and on field trials around the world. KWS also pays a dividend and has made acquisitions over the years to expand into new crops and regions. The main risks: weather and commodity prices swing farmers' incomes, big competitors keep consolidating, and regulatory fights over gene editing could slow its newest tools.
Saved answer · last researched 12 Nov 2026